Cytomed Therapeutics Limited Stock Fundamentals
| GDTC Stock | 1.52 0.01 0.65% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess CytoMed Therapeutics' long-term financial health and intrinsic value.
At present, CytoMed Therapeutics' Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Net Interest Income is expected to grow to about 312.2 K, whereas Other Operating Expenses is forecasted to decline to about 1.5 M. CytoMed | Select Account or Indicator | Build AI portfolio with CytoMed Stock |
CytoMed Therapeutics Limited Company Operating Margin Analysis
CytoMed Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current CytoMed Therapeutics Operating Margin | (4.52) % |
Most of CytoMed Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CytoMed Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CytoMed Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for CytoMed Therapeutics is extremely important. It helps to project a fair market value of CytoMed Stock properly, considering its historical fundamentals such as Operating Margin. Since CytoMed Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CytoMed Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CytoMed Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
CytoMed Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, CytoMed Therapeutics Limited has an Operating Margin of -4.5217%. This is 87.11% lower than that of the Biotechnology sector and 95.97% lower than that of the Health Care industry. The operating margin for all United States stocks is 17.94% lower than that of the firm.
CytoMed Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CytoMed Therapeutics's current stock value. Our valuation model uses many indicators to compare CytoMed Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CytoMed Therapeutics competition to find correlations between indicators driving CytoMed Therapeutics's intrinsic value. More Info.CytoMed Therapeutics Limited is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . At present, CytoMed Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CytoMed Therapeutics' earnings, one of the primary drivers of an investment's value.CytoMed Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CytoMed Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CytoMed Therapeutics could also be used in its relative valuation, which is a method of valuing CytoMed Therapeutics by comparing valuation metrics of similar companies.CytoMed Therapeutics is currently under evaluation in operating margin category among its peers.
CytoMed Fundamentals
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (4.52) % | ||||
| Current Valuation | 16.12 M | ||||
| Shares Outstanding | 11.73 M | ||||
| Shares Owned By Insiders | 67.35 % | ||||
| Shares Owned By Institutions | 0.43 % | ||||
| Number Of Shares Shorted | 27.48 K | ||||
| Price To Book | 3.25 X | ||||
| Price To Sales | 24.60 X | ||||
| Revenue | 52.01 K | ||||
| Gross Profit | 675.25 K | ||||
| EBITDA | (1.79 M) | ||||
| Net Income | (1.84 M) | ||||
| Total Debt | 339.2 K | ||||
| Book Value Per Share | 0.62 X | ||||
| Cash Flow From Operations | (1.69 M) | ||||
| Short Ratio | 0.10 X | ||||
| Earnings Per Share | (0.25) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 43 | ||||
| Beta | -0.35 | ||||
| Market Capitalization | 22.53 M | ||||
| Total Asset | 7.37 M | ||||
| Retained Earnings | (10.87 M) | ||||
| Working Capital | 5.39 M | ||||
| Net Asset | 7.37 M |
About CytoMed Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CytoMed Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytoMed Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytoMed Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 109.2 K | 114.6 K | |
| Total Revenue | 52 K | 49.4 K | |
| Cost Of Revenue | 22.7 K | 24.8 K | |
| Sales General And Administrative To Revenue | 23.88 | 25.07 | |
| Research And Ddevelopement To Revenue | 27.48 | 28.85 | |
| Capex To Revenue | 19.71 | 20.70 | |
| Ebit Per Revenue | (50.50) | (53.02) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CytoMed Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytoMed Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomed Therapeutics Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomed Therapeutics Limited Stock:Check out CytoMed Therapeutics Piotroski F Score and CytoMed Therapeutics Altman Z Score analysis. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share | Quarterly Revenue Growth 1.01 | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.